PJA1 Antibody
Description
Introduction to PJA1 Antibody
The PJA1 antibody is a specialized immunological tool targeting the Praja Ring Finger Ubiquitin Ligase 1 (PJA1), an E3 ubiquitin ligase encoded by the PJA1 gene located on the X chromosome. This antibody is critical for detecting PJA1 in research settings, enabling studies on its roles in protein degradation, disease mechanisms, and therapeutic targeting .
Structure and Function of PJA1
PJA1 contains a RING finger domain essential for its E3 ubiquitin ligase activity, which facilitates the transfer of ubiquitin to substrate proteins, marking them for proteasomal degradation . Key functional attributes include:
Role in Neurodegenerative Diseases
-
PolyQ Aggregate Clearance: PJA1 ubiquitinates pathogenic polyQ proteins (e.g., mutant ataxin-3 in spinocerebellar ataxia type 3), reducing their aggregation in neuronal cells. Silencing PJA1 increases polyQ protein levels by 5–6 fold .
-
Mechanistic Insight: The RING domain is critical for activity; deletion or mutation (e.g., H553S) abolishes PJA1’s ability to degrade polyQ proteins .
-
In Vivo Validation: Overexpression of PJA1 rescues neurodegeneration in Drosophila models of SCA3 .
Role in Cancer Chemoresistance
-
PGAM5 Degradation: PJA1 ubiquitinates PGAM5 (a mitochondrial phosphatase), promoting its proteasomal degradation via K48-linked ubiquitination. This suppresses GSDME-mediated pyroptosis, enhancing docetaxel resistance in nasopharyngeal carcinoma (NPC) .
-
Clinical Relevance: High PJA1 expression correlates with poor survival in NPC patients (HR = 2.45 for OS; p < 0.001) and reduced efficacy of TPF induction chemotherapy .
Diagnostic Utility
-
Immunohistochemistry (IHC): PJA1 antibodies are used to stratify NPC patients into high- and low-expression cohorts, predicting chemoresistance and survival outcomes .
Therapeutic Targeting
-
Small-Molecule Inhibition: RTA402, a PJA1 inhibitor, sensitizes NPC cells to docetaxel in vitro and in vivo, reducing tumor growth by 60% in xenograft models .
-
Knockdown Effects: PJA1 silencing increases docetaxel-induced pyroptosis (e.g., LDH release ↑2.5-fold; caspase-3 activation ↑3-fold) .
Future Directions
-
Therapeutic Development: Optimizing PJA1 inhibitors like RTA402 for clinical trials in neurodegenerative and oncology settings.
-
Biomarker Validation: Expanding IHC-based PJA1 testing to other cancers linked to ubiquitin-proteasome dysregulation.
Product Specs
Target Background
- Research findings provide insights into novel aspects of Praja1 function. PMID: 21461837
- These results suggest a role for PRAJA1 in regulating the level of PRC2 by targeting its free subunits for ubiquitin-mediated proteasomal degradation. PMID: 21513699
- A RING finger protein Praja1 regulates Dlx5-dependent transcription through its ubiquitin ligase activity for the Dlx/Msx-interacting MAGE/Necdin family protein, Dlxin-1. PMID: 11959851
- PRAJA1 is involved in protein ubiquitination in the brain. It is a candidate gene for X-linked mental retardation. PMID: 12036302
Q&A
Basic Research Questions
How do I validate PJA1 antibody specificity in protein degradation studies?
Validation requires a multi-step approach:
-
Knockdown/knockout controls: Use siRNA or CRISPR-Cas9 to reduce PJA1 expression. Successful validation is achieved if antibody signal intensity correlates with protein levels (e.g., 5–6-fold increase in polyQ proteins after PJA1 silencing ).
-
Isoform discrimination: Compare observed vs. predicted molecular weights. PJA1 migrates at 71–80 kDa in SDS-PAGE due to post-translational modifications .
-
Functional assays: Demonstrate reduced polyQ aggregate formation (e.g., ataxin-3 or huntingtin) upon PJA1 overexpression .
Table 1: Antibody validation benchmarks
What criteria determine antibody selection for studying PJA1’s E3 ligase activity?
Prioritize antibodies with:
-
Domain specificity: Antibodies targeting the RING domain (aa 154–183) block ubiquitination activity .
-
Species cross-reactivity: Rabbit polyclonal antibodies show consistent reactivity in human, mouse, and rat models .
-
Functional validation: Use antibodies proven in ubiquitination assays (e.g., reduced PGAM5 stability upon PJA1 overexpression ).
Advanced Experimental Design
How do I resolve conflicting data on PJA1’s role in viral restriction vs. protein homeostasis?
Context-dependent methodology:
-
Pathway segregation:
Table 2: PJA1 functional contexts
What optimization is required for co-IP studies of PJA1-protein interactions?
-
Buffer composition: Use high-stringency RIPA buffer (1% NP-40, 0.5% sodium deoxycholate) to minimize nonspecific binding .
-
Crosslinking: Apply formaldehyde (1% for 10 min) to preserve transient interactions like PJA1-NSE4 .
-
Antibody ratio: 0.5–4 µg antibody per 1–3 mg lysate, as per empirical validation .
How should I interpret variable PJA1 subcellular localization across studies?
Localization depends on:
-
Cell type: Nuclear-cytoplasmic distribution in NPC vs. neuronal cells .
-
Stress conditions: Docetaxel treatment increases mitochondrial PJA1-PGAM5 colocalization .
-
Isoform expression: Alternate splicing generates 50 kDa/65 kDa isoforms with distinct trafficking .
Methodological recommendation: Combine subcellular fractionation with isoform-specific antibodies (e.g., N-terminal vs. RING domain-targeting ).
Data Interpretation Challenges
How to address discrepancies in ubiquitination assay results?
-
Ubiquitin chain specificity: Use K48- vs. K63-linkage antibodies to distinguish proteasomal degradation (PJA1-PGAM5 ) from signaling roles.
-
Protease inhibition: Include MG132 (10 µM) to stabilize ubiquitinated substrates .
-
Negative controls: Co-IP with RING-deleted PJA1 (ΔRING) to confirm E3 ligase dependency .
What controls are essential for PJA1 immunohistochemistry in clinical samples?
-
Adjacent normal tissue: Assess baseline expression in nasopharyngeal epithelium vs. tumors .
-
Staining intensity quantification: Use H-scores (0–300 scale) validated in 279 NPC samples .
-
Preabsorption control: Incubate antibody with immunogen peptide (10x molar excess) to confirm signal specificity .
